Skip to content
Back
  • Home
  • About us
    • Management
    • Board
    • Team
    • Scientific advisory board
    • Partnerships
    • Investors
  • Our science
  • Pipeline
    • Pipeline
    • CP-012
    • CP-101
    • CP-102
    • CP-301
    • CP-106
    • CP-107
    • CP-108
  • News
    • Press releases
  • Contact
    • Business Development
    • Social network
    • Career

Partnerships

Our partnerships

Bukwang

Bukwang Pharm. Co. (www.bukwang.co.kr), Ltd. is a leading Korean pharmaceutical company listed on the Korean Stock Exchange [KRX:003000]. The company has been in business for over 50 years, and achieved US$150 million in sales in 2020. Sales are primarily derived from products licensed from Europe, the United States, and Japan. The company is currently investing significant resources in R&D to create a robust pipeline of preclinical and clinical agents for the treatment of antiviral diseases, gastrointestinal disorders, CNS disorders and metabolic disease.

BDD Pharma

BDD Pharma Ltd (www.bddpharma.com) is a privately-owned drug delivery company specializing in the development of modified and controlled release oral formulations. BDD’s OralogiK™ technology is a tablet-in-tablet drug delivery system providing timed release, targeted release and the opportunity for complex bi- and tri-phasic release of one or multiple drugs. The OralogiK™ technology is protected with granted patents across a number of territories including the US, EU and Japan. Supported by investment from Archangels, the Scottish Investment Bank, Alderley Park Ventures and BioCity Investments, BDD has in-house clinical trial capabilities for the conduct of gamma scintigraphic/ pharmacokinetic studies in humans. BDD’s SWIFT adaptive clinical trials integrate formulation development, GMP manufacturing and clinical testing into one streamlined service, offering a more flexible approach than the conventional clinical trial design structure.

Recent News

March 14, 2025
Contera Pharma announces that CP0014753, a novel antisense oligonucleotide developed for the treatment of Canavan disease, is ready for IND-enabling studies
Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the preclinical candidate nomination of CP0014753, a…
Read more
December 03, 2024
Contera Pharma Welcomes New Board Members to Drive Strategic Growth
[Hørsholm, Denmark – December 03, 2024] – Contera Pharma A/S, a clinical-stage biotech company pioneering treatments for neurological disorders, is proud to…
Read more

View all news

Contact us

Denmark map icon

Contera Pharma

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

Thomas Sager, CEO
info@conterapharma.com

 

Contact us

Contera Pharma

Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark

 

Thomas Sager, CEO

info@conterapharma.com

 

Connect on Linkedin

Useful links

About us

Our Science

Pipeline

News

Contact

Cookie policy

Privacy policy